Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry

Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry

Abstract Background The direct factor Xa inhibitor rivaroxaban is approved for the treatment of venous thromboembolism (VTE), based on the results of large phase III trials. Objectives To confirm rivaroxaban's effectiveness and safety in routine clinical care of patients with VTE. Methods Data...

Full description

Bibliographic Details
Main Authors: Stephanie Müller, Luise Tittl, Victoria Speed, Lara Roberts, Jignesh Patel, Raj Patel, Roopen Arya, Nils Kucher, David Spirk, Kurtulus Sahin, Jan Beyer‐Westendorf
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
anticoagulant
hemorrhage
registries
rivaroxaban
venous thromboembolism
Online Access:https://doi.org/10.1002/rth2.12829

Internet

https://doi.org/10.1002/rth2.12829

Similar Items